# OnCo record cutaneous-scc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cutaneous-scc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cutaneous-scc" ;
  schema:name "Cutaneous squamous cell carcinoma"@en ;
  schema:alternateName "cSCC"@en, "Squamous Cell Carcinoma of the Skin"@en ;
  schema:description "Cutaneous squamous cell carcinoma is a sun-related skin cancer with over a million US cases a year, almost all cured by removing them. The 2 to 5% that grow deep or spread respond to PD-1 immunotherapy (cemiplimab, pembrolizumab), which is now also given after surgery in high-risk cases; transplant recipients cannot safely receive it."@en ;
  schema:url <https://onco.cc/cancers/cutaneous-scc/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Squamous-cell_carcinoma_of_the_skin> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465>, <https://doi.org/10.1056/NEJMoa2502449>, <https://www.cancer.gov/types/skin/patient/skin-treatment-pdq> ;
  onco:tag "gap-fill", "skin" ;
  onco:related <https://onco.cc/cancers/basal-cell-carcinoma/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/merkel-cell-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/black-salve-escharotics/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/imiquimod/>, <https://onco.cc/drugs/aminolevulinic-acid/>, <https://onco.cc/drugs/acitretin/>, <https://onco.cc/drugs/nicotinamide/> ;
  onco:companies <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/summit-therapeutics/>, <https://onco.cc/companies/replimune/>, <https://onco.cc/companies/rakuten-medical/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/nct06585410/>, <https://onco.cc/trials/empower-cscc-1/> ;
  onco:pipeline <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/hmbd-001/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/> .